24 Recruiting Studies Using Relatlimab
Active clinical trials that use this intervention, sourced directly from the NIH registry.
Browse by conditionTrials Using Relatlimab
Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC)
📍 Sidney Kimmel Comprehensive Cancer Center — Baltimore, Maryland
Hepatocellular Carcinoma
View Study & Checklist ➔REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer
📍 Johns Hopkins University — Baltimore, Maryland
Gastroesophageal Cancer
View Study & Checklist ➔Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer
📍 Johns Hopkins University — Baltimore, Maryland
Gastric Cancer
View Study & Checklist ➔ARID1A and/or KDM6A Mutation and CXCL13 Expression
📍 M D Anderson Cancer Center — Houston, Texas
Locally Advanced Bladder Urothelial Carcinoma
View Study & Checklist ➔Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Advanced Lymphoma
View Study & Checklist ➔Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor
📍 Cedars Sinai Medical Center — Los Angeles, California
Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy
View Study & Checklist ➔Phase II Trial of Immunotherapy in Patients With Carcinomas Arising From the Renal Medulla
📍 MD Anderson Cancer Center — Houston, Texas
Carcinomas
View Study & Checklist ➔PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma
📍 Massachusetts General Hospital Cancer Center — Boston, Massachusetts
Metastatic Melanoma
View Study & Checklist ➔A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations
📍 Local Institution - 0007 — Anchorage, Alaska
Melanoma
View Study & Checklist ➔A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma
📍 Local Institution - 0010 — Tucson, Arizona
Melanoma
View Study & Checklist ➔Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer
📍 UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania
Head and Neck Squamous Cell Carcinoma (HNSCC)
View Study & Checklist ➔Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY)
📍 The University of Texas M. D. Anderson Cancer Center — Houston, Texas
Melanoma
View Study & Checklist ➔Neoadjuvant Nivolumab + Relatlimab (Opdualag) Versus Nivolumab for Resectable High-Risk Basal Cell Carcinoma
📍 University of California, Irvine — Irvine, California
Basal Cell Carcinoma
View Study & Checklist ➔Pan Tumor Rollover Study
📍 Local Institution - 0220 — Huntsville, Alabama
Cancer
View Study & Checklist ➔ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab
📍 NYU Langone Health — New York, New York
Metastatic Melanoma
View Study & Checklist ➔Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab
📍 Memorial Sloan Kettering Cancer Center — New York, New York
Newly Diagnosed Glioblastoma
View Study & Checklist ➔Saci Nivo Rela for TNBC
📍 Yale University — New Haven, Connecticut
Metastatic Triple-negative Breast Cancer
View Study & Checklist ➔A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
📍 Local Institution - 0487 — Mobile, Alabama
Non-small Cell Lung Cancer
View Study & Checklist ➔A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
📍 Ironwood Cancer & Research Centers — Chandler, Arizona
Melanoma
View Study & Checklist ➔Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
📍 Cancer Center at Saint Joseph's — Phoenix, Arizona
Muscle Invasive Bladder Urothelial Carcinoma
View Study & Checklist ➔Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in Unresectable or Metastatic Melanoma
📍 UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania
Locally Advanced Melanoma
View Study & Checklist ➔Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
📍 Kaiser Permanente Dublin — Dublin, California
Metastatic Nasopharyngeal Carcinoma
View Study & Checklist ➔Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma
📍 Johns Hopkins Hospital — Baltimore, Maryland
Basal Cell Carcinoma
View Study & Checklist ➔Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases
📍 M D Anderson Cancer Center — Houston, Texas
Melanoma (Skin)
View Study & Checklist ➔